Wedge Therapeutics

Wedge Therapeutics is a pre-clinical stage biotechnology company dedicated to discovering and developing a new class of small molecule medicines. The company leverages a proprietary platform to design 'wedge' molecules, which function as molecular glues to create and stabilize novel protein-protein interactions. By recruiting E3 ligases to specific disease-causing targets, Wedge aims to induce the degradation of proteins that are currently considered undruggable. This approach allows for the precise modulation of biological pathways that have been difficult to reach with traditional therapeutic modalities. Headquartered in Cambridge, Massachusetts, the company is backed by Atlas Venture and focuses on high-impact therapeutic areas including oncology and immunology.